trial · primary record
Visugromab (CTL-002)
Cancer-associated Cachexia
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 518 |
| Primary completion | 2030-12 |
| Primary endpoint | Change from baseline in body weight at 12 weeks |
| Registry ID | NCT07112196 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:29.155Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07112196
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.